European Heart Journal Advance Access originally published online on May 26, 2006
European Heart Journal 2006 27(15):1876-1883; doi:10.1093/eurheartj/ehl044
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy
1 Department of Cardiology, Tel Aviv Sourasky Medical Center and The Sackler Faculty of Medicine, Tel Aviv University Israel
2 The Hematology Institute, Tel Aviv Sourasky Medical Center and The Sackler Faculty of Medicine, Tel Aviv University Israel
Received 22 December 2005; revised 15 April 2006; accepted 4 May 2006; online publish-ahead-of-print 26 May 2006.
* Corresponding author. Tel: +972 3 6974250; fax: +972 3 5469832.E-mail address: jacobg{at}post.tau.ac.il
See page 1767 for the editorial comment on this article (doi:10.1093/eurheartj/ehl128)
Aims Doxorubicin (Dox) is a potent chemotherapeutic agent associated with severe cardiotoxicity. Erythropoietin (Epo) has recently been shown to exhibit proangiogenic properties related to endothelial progenitor cell (EPC) mobilization. We tested the hypothesis that EPC are compromised in rats with Dox-induced cardiotoxicity and correction of this functional impairment by treatment with Epo could result in attenuation of myocardial dysfunction.
Methods and results Wistar rats were either treated with two different doses of Epo (20U or 200U) or PBS (n = 40 in each group) for four consecutive weeks, followed by Dox administration. In a second study, EPC obtained from healthy rats were transfused intravenously (n = 20/group) prior to induction of Dox cardiomyopathy. EPC from healthy subjects were evaluated for their proliferative and migratory properties in the presence or absence of Dox and Epo pre-treatment.
Echocardiography demonstrated an improvement in fractional shortening (FS) in Epo-treated rats. Epo treatment was associated with a reduced mortality in both Epo-treated groups. Circulating EPC numbers were three times higher in Epo-treated compared with non-treated animals. Adhesive properties, migration, and tube formation capacity in matrigel of EPCs from both Epo-treated groups as compared with controls were significantly enhanced. EPC transfer to Dox-treated rats led to functional myocardial improvement equivalent to the protection afforded by treatment with Epo. In EPC obtained from humans, pre-incubation with Epo significantly attenuated the anti-proliferative and anti-migratory effects of treatment with Dox.
Conclusion Epo treatment is potentially protective against myocardial dysfunction induced by Dox. These effects are partially mediated by enhancement in the number of EPC and their functional properties.
Key Words: EPC • Epo • Cardiomyopathy • Stem cell • Cell therapy
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Epo ‘cytokine-doping’ of heart disease patients, will it work?
- Erik Jørgensen, Lene Bindslev, Rasmus Sejersten Ripa, and Jens Kastrup
EHJ 2006 27: 1767-1768.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  D. E. Burger, F.-L. Xiang, L. Hammoud, D. L. Jones, and Q. Feng Erythropoietin Protects the Heart from Ventricular Arrhythmia during Ischemia and Reperfusion via Neuronal Nitric-Oxide Synthase J. Pharmacol. Exp. Ther., June 1, 2009; 329(3): 900 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Lin, Y.-S. Chen, H.-S. Chiang, and M.-C. Ma Hypoxic preconditioning protects rat hearts against ischaemia-reperfusion injury: role of erythropoietin on progenitor cell mobilization J. Physiol., December 1, 2008; 586(23): 5757 - 5769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rastogi, M. Imai, V. G. Sharov, S. Mishra, and H. N. Sabbah Darbepoetin-{alpha} prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failure Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2475 - H2482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. George Erythropoietin and outcome prediction in patients with heart failure: the plot thickens... Eur. Heart J., June 2, 2008; 29(12): 1481 - 1482. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ramond, E. Sartorius, M. Mousseau, C. Ribuot, and M. Joyeux-Faure Erythropoietin Pretreatment Protects Against Acute Chemotherapy Toxicity in Isolated Rat Hearts Experimental Biology and Medicine, January 1, 2008; 233(1): 76 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Lipsic, B. D. Westenbrink, P. van der Meer, P. van der Harst, A. A. Voors, D. J. van Veldhuisen, R. G. Schoemaker, and W. H. van Gilst Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit Eur J Heart Fail, January 1, 2008; 10(1): 22 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Joyeux-Faure Cellular Protection by Erythropoietin: New Therapeutic Implications? J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 759 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Westenbrink, E. Lipsic, P. van der Meer, P. van der Harst, H. Oeseburg, G. J. Du Marchie Sarvaas, J. Koster, A. A. Voors, D. J. van Veldhuisen, W. H. van Gilst, et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization Eur. Heart J., August 2, 2007; 28(16): 2018 - 2027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Jorgensen, L. Bindslev, R. S. Ripa, and J. Kastrup Epo 'cytokine-doping' of heart disease patients, will it work? Eur. Heart J., August 1, 2006; 27(15): 1767 - 1768. [Full Text] [PDF]
|
|